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KCa3.1 inhibition switches the phenotype of
glioma-infiltrating microglia/macrophages
A Grimaldi1, G D'Alessandro1,2, MT Golia1, EM Grössinger3, S Di Angelantonio1,4, D Ragozzino1,2, A Santoro5, V Esposito2,5, H Wulff3,
M Catalano1,2,7 and C Limatola2,6,7
Among the strategies adopted by glioma to successfully invade the brain parenchyma is turning the infiltrating microglia/
macrophages (M/MΦ) into allies, by shifting them toward an anti-inflammatory, pro-tumor phenotype. Both glioma and infiltrating
M/MΦ cells express the Ca2+-activated K+ channel (KCa3.1), and the inhibition of KCa3.1 activity on glioma cells reduces tumor
infiltration in the healthy brain parenchyma. We wondered whether KCa3.1 inhibition could prevent the acquisition of a pro-tumor
phenotype by M/MΦ cells, thus contributing to reduce glioma development. With this aim, we studied microglia cultured in glioma-
conditioned medium or treated with IL-4, as well as M/MΦ cells acutely isolated from glioma-bearing mice and from human glioma
biopsies. Under these different conditions, M/MΦ were always polarized toward an anti-inflammatory state, and preventing KCa3.1
activation by 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34), we observed a switch toward a pro-inflammatory,
antitumor phenotype. We identified FAK and PI3K/AKT as the molecular mechanisms involved in this phenotype switch, activated
in sequence after KCa3.1. Anti-inflammatory M/MΦ have higher expression levels of KCa3.1 mRNA (kcnn4) that are reduced by
KCa3.1 inhibition. In line with these findings, TRAM-34 treatment, in vivo, significantly reduced the size of tumors in glioma-bearing
mice. Our data indicate that KCa3.1 channels are involved in the inhibitory effects exerted by the glioma microenvironment on
infiltrating M/MΦ, suggesting a possible role as therapeutic targets in glioma.
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Among primary brain tumors, glioblastoma multiforme (GBM)
is the most aggressive form. Even after surgical ablation and
routine treatments with chemo- and radio-therapeutic agents,
patient survival remains o15 months.1 A wide spectrum of
new therapeutic strategies is under investigation, including
genetic and immunological approaches, but the need for new
possible targets remains urgent. As in other tumors, the
immune system has a central role in GBM, contributing to
tumor progression and metastasis;2 for this reason, a novel
research field is focused on immunotherapy-based drug
discovery. Microglia represent important constituents of the
innate immune system of the nervous system. However, in
GBM, this first-line defensive system is hijacked by cytokines
released by the tumor.3
Under physiological conditions, microglia continuously
monitor the surrounding parenchyma with active movement
of cell processes that extend and retract to sense potentially
toxic local alterations.4,5 In addition to this patrolling pheno-
type, mainly associated with a ramified shape, microglia
assume additional intermediate states, culminating in a fully
amoeboid shape.6 The transition from ramified to amoeboid
shape, together with the acquisition of specific functional
and molecular characteristics, generates several intermediate
phenotypes that represent different activation states: the
extremes of this transition comprise, in analogy with the
dichotomy described for macrophages, dynamic changes
from a pro-inflammatory, M1-like phenotype, to an anti-
inflammatory one, namely M2, including a plethora of sub-
phenotypes (M2a, M2b, M2c).7
Tumor-associated microglia/macrophages (M/MΦ) are
polarized toward an anti-inflammatory phenotype under the
action of cytokines and factors released by tumor cells8–10 and
contribute to further release of soluble factors, which influence
tumor growth and behavior.11,12 A wide range of studies aim
to induce tumor- associated macrophages to switch from the
pro-tumor to the antitumor pro-inflammatory phenotype.13
One promising target to control microglia phenotype is
the Ca2+-activated K+ channel (KCa3.1), which is involved
in microglia activation in different pathological conditions such
as glioma,14 spinal cord injury,15 ischemia16 and Alzheimer’s
Disease.17 In particular, KCa3.1 blockade reduced infarct
area and glioma invasiveness in rodent models of cerebral
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ischemia and cerebral tumor14,16 and reduced the neurotoxi-
city of microglia upon lipopolysaccharide (LPS) or oligomeric
amyloid β exposure.18,19 Interestingly, KCa3.1 expression
level negatively correlates with patient prognosis.20
In this paper, we investigated the effect of KCa3.1 inhibition
on the phenotype switching of microglia induced by GBM-
conditioned medium (GCM) or by interleukin (IL)-4, a cytokine
involved in microglia polarization toward the anti-inflammatory
phenotype. We demonstrated that, upon KCa3.1 inhibition by
1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34),
the GBM- or IL-4-induced profile of M/MΦ is more polarized
toward an inflammatory phenotype. This effect is confirmed,
ex vivo, in human specimens from glioma patients and, in vivo,
in a mouse model of glioma, where TRAM-34 treatment
induced an increase of pro-inflammatory and a reduction of
anti-inflammatory gene expression in infiltrating CD11b+ cells.
This polarization corresponded to a reduced tumor size in
TRAM-34-treated glioma-bearing mice, further supporting
the antitumor effect of inflammatory M/MΦ cells. We also
described the molecular mechanisms involved in these
modulatory effects, demonstrating the involvement of the
focal adhesion kinase (FAK) and phosphoinositide-3 kinase/
protein kinase B (PI3K/AKT) signaling pathways.
Results
We have previously demonstrated that KCa3.1 expression on
glioma cells is involved in tumor cell migration in cerebral
parenchyma.14 As KCa3.1 channels in the brain are also
expressed by microglia and infiltrating macrophages (M/MΦ),
we now investigated the effect of KCa3.1 blockage on M/MΦ
cells, with particular interest on the acquisition of pro-tumor or
antitumor phenotype.
It is known that the M/MΦ cell population is deeply
influenced by soluble factors produced by tumor cells.9,10
Data in Figure 1a indicate that CD11b+ cells (mainly
represented by M/MΦ) isolated from the brain hemisphere
ipsilateral to glioma cells injection do express typical anti-
inflammatory genes (arg1, ym1, fizz1, cd163 and cd206), with
pro-tumor activity that, upon TRAM-34 treatment, undergo a
significant reduction of expression. Interestingly, pro-inflam-
matory, anti-tumor genes (cd86, tnfα, inos, il1β and il6), whose
expression is not different in the two cerebral hemispheres,
regardless of tumor presence (with the only exception being
represented by inos), are remarkably increased in the glioma
ipsilateral hemisphere of TRAM-34-treated mice. Interestingly,
when TRAM-34-treated mice were analyzed for tumor growth,
a significant reduction of tumor volume was observed
(Figure 1b).
Similar results were obtained when CD11b+ cells were
isolated from tumoral tissue obtained from GBM patients
undergoing surgery: upon TRAM-34 treatment, these cells
had a significant reduction of human anti-inflammatory
markers (CD163, MMP12) and a significant increase of
human pro-inflammatory markers (CXCL10, IL12A, NOS2
and TNF)21 (Figure 1c), confirming in human GBM the data
obtained in glioma-bearing mice.
To better investigate the molecular mechanisms involved in
this potassium channel-dependent phenotype switch of
M/MΦ, we used primary murine microglia exposed to GCM
or non-conditioned medium (NCM) for 24 h. Data shown in
Figure 2a show that, similarly to what observed ex vivo,
cell exposure to GCM induced an increased expression of
anti-inflammatory genes; TRAM-34 treatment reduced
their expression and increased the transcription of pro-
inflammatory genes. Similar phenotypic switch was observed
when cultured microglia were polarized by cytokine treatment
(48 h with LPS/interferon-γ (IFNγ) or IL-4) and treated
with TRAM-34; also, in these conditions the expression of
anti-inflammatory genes was reduced with an increase of pro-
inflammatory genes upon KCa3.1 inhibition (Supplementary
Figure S1A).
The activation state of microglia has been often correlated
with their shape, although it is not possible to strictly associate
a morphology to a specific phenotype.6 A ramified microglia
has often been related to a less active, resting phenotype, in
comparison with round, amoeboid, active cells. However, this
simplified view has been challenged by the description of the
continuous monitoring activity of ramified microglia, demon-
strating that these cells are not really resting and should
probably rather be called 'surveillant'.4 We measured the
ramification grade of microglia calculating the 'form factor', a
parameter taken as 1 for round cells and correspondingly
o1 when the morphology deviates from the spherical shape.
Figure 2b shows that microglia exposed to GCM have a
decreased form factor versus NCM-exposed cells and that
TRAM-34 treatment significantly reverts this effect. Similar
results were obtained when microglia were treated in vitrowith
LPS/IFNγ or IL-4 (Supplementary Figure S1B).
To test whether microglia phenotypes correlatewith different
expression levels of KCa3.1, real-time PCR (RT-PCR)
analyses were performed on CD11b+ cells isolated from the
brain of GL261-bearingmice, or from humanGBM specimens,
and on NCM- and GCM-exposed or cytokine-polarized
microglia. A significant higher expression of KCa3.1 (kcnn4
gene) was observed in CD11b+ cells isolated from the
ipsilateral cerebral hemisphere of glioma-bearing mice in
comparison with the contralateral hemisphere and this
difference was totally abolished by TRAM-34 treatment
(Figure 3a, left). The expression level of kcnn4 in CD11b+
cells isolated from the contralateral hemisphere was always
comparable with the level measured in control healthy mice
(data not shown). In accordance, KCa3.1 level was reduced
upon TRAM-34 treatment in M/MΦ cells (Iba1+) infiltrating the
tumor area (Figure 3a, center and right). Consistently, when
CD11b+ cells isolated from human GBM specimens were
treated with TRAM-34 for 24 h, a significant reduction of
KCNN4 expression was observed (Figure 3b). Similar results
were obtained on cultured microglia upon GCM (Figure 3c)
and IL-4 (Figure 3d) treatment, and KCa3.1 inhibition
abolished the effect. Taken together, these data suggest that
the activity of KCa3.1 channels modulates both microglia
phenotype and channel expression.
Modulation of channel expression was confirmed by
functional analysis: cytokine-polarized microglia were tested
for KCa3.1-mediated currents by patch-clamp recordings.
Data shown in Figure 3e demonstrate the presence of
large, 5-(4-phenoxybutoxy)psoralen (PAP-1)-sensitive voltage-
activated K+ channel (Kv1.3) currents for LPS/IFNγ-treated
microglia, together with barely detectable TRAM-34-sensitive
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currents (inset, 16.05±7.34 pS/pF). In contrast, IL-4-treated
microglia had no significant Kv1.3 currents (not shown),
with a more prominent TRAM-34-sensitive component
(19.45±12.68 pS/pF) confirming the tendency to a prefer-
ential expression of these channels on microglia with anti-
inflammatory features.
We have previously shown that GCM exposure modulates
microglia migration and phagocytic activity and that KCa3.1
inhibition abolished these effects.14 We confirmed these data
by performingmigration, invasion and phagocytosis assays on
primary murine microglia exposed to medium conditioned by
GL261 (Figure 4a), U87MG and GL15 (Supplementary
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Figure 1 KCa3.1 inhibition modifies the polarization of CD11b+ cells extracted from glioma-bearing mice and from biopsies of human GBM. (a) RT-PCR of M2-like (arg1, ym1,
fizz1, cd163 and cd206) and M1-like (cd86, tnfα, inos, il1β and il6) related genes in CD11b+cells extracted from ipsilateral and contralateral cerebral hemispheres of GL261-
bearing mice treated with vehicle (C) or TRAM-34 (T, 120 mg/kg/die). Data are the mean± S.E.M., *Po0.05 versus C contralateral; #Po0.05 versus C ipsilateral by two-way
ANOVA; N= 8. (b) Tumor volumes in the brain of mice treated with vehicle or TRAM-34. Data are the mean± S.E.M., *Po0.05 by Student's t-test; N= 8. Scale bar: 1 mm.
(c) RT-PCR for human M2-like (CD163, MMP12, TGFB1) and M1-like (CXCL10, IL12A, NOS2, TNF) related genes expressed by CD11b+ cells extracted from human GBM
specimens and treated for 24 h with TRAM-34 (2.5 μM). Data are expressed as fold change of TRAM-34-treated versus untreated samples and are the mean± S.E.M., *Po0.05
by Student's t-test; N= 4
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Figure S2) glioma cell lines, in the presence of TRAM-34,
finding that KCa3.1 block inhibited all the activities potentiated
by GCM (Figure 4a). To further support these results, we used
a specific activator of KCa3.1, naphtho[1,2-d]thiazol-2-yla-
mine (SKA-31), and found that treatment with this compound
increased microglia migration, invasion and phagocytic
activity (Figure 4b). Moreover, we analyzed the same activities
in primary murine microglia treated with LPS/IFNγ or IL-4,
demonstrating that only IL-4-treated microglia had increased
phagocytic, chemotactic and invasive properties (similarly to
GCM-exposed microglia). KCa3.1 inhibition impaired these
functional modulations, being ineffective on LPS/IFNγ-stimu-
latedmicroglia (Figure 4c). To further investigate this effect, we
decided to study whether cytokine stimulation modulated the
expression levels of receptors for chemokines or MMPs. IL-4
treatment induced increased expression of CXCR4, CXCR6
and MMP-9 on microglia, while LPS/IFNγ treatment was
ineffective (on CXCR6 and MMP-9) or drastically inhibitory
(on CXCR4). TRAM-34 abolished the effects of IL-4 on
chemokine receptors and MMP-9 expression (Supplementary
Figure S3A). Consistently, IL-4-treated cells migrated more
toward CXCL12 and CXCL16 (Supplementary Figure S3B).
MTTassay excluded "that the effects of GCM and IL-4 was on
cell proliferation," some increase being only observed for LPS/
IFNγ-treated cells (Supplementary Figure S3C).
It has been demonstrated that the exposure of microglia to
soluble factors released by glioma cells induces the activation
of the PI3K/Akt and FAK pathways and that these signaling
pathways are involved in cell movement and phago-
cytosis.22,23 Having demonstrated that anti-inflammatory
microglia have increased migratory and phagocytic activity
(Figure 4c) and higher functional expression of kcnn4
(Figure 3), we wanted to verify the hypothesis that KCa3.1
activity could contribute to the phenotype switch of microglia
through the modulation of these signaling pathways. We
observed that GCM-exposed microglia have increased
FAK and AKT phosphorylation, significantly reduced by
TRAM-34 treatment, demonstrated both by western blotting
and immunofluorescence analysis (Figure 5a and Supple-
mentary Figure S4). Moreover, GCM-induced migration,
invasion and phagocytosis were completely inhibited in the
presence of FAK (PF-228) and PI3K/AKT (LY294002)
inhibitors (Figure 5b). To investigate whether KCa3.1 activa-
tion has effect on FAK and PI3K/AKT pathways, cultured
microglia were treated with SKA-31, a channel activator. Data
shown in Figure 5c demonstrate that both FAK and AKT
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Figure 2 KCa3.1 inhibition reverts GCM-induced microglia polarization. (a) RT-PCR on mRNAs of microglia treated with NCM or GCM in the absence (C) or presence of
TRAM-34 (T, 2.5 μM), analyzed for the expression of M2-like (arg1, ym1, fizz1, cd163 and cd206) and M1-like (cd86, tnfα, inos, il1β and il6) related genes. Data are expressed
as fold increase and are the mean± S.E.M.; *Po0.05 versus NCM; #Po0.05 versus GCM/C by two-way ANOVA and paired t-test for inos; N= 8. (b) NCM- and
GCM-treated microglia in the absence (C) or presence of TRAM-34 (T, 2.5 μM), stained with phalloidin (green) and Hoechst (blue). Scale bar: 20 μm. Form factor values
(calculated as reported in the Materials and Methods section) are shown in the graph and are the mean±S.E.M., *Po0.05 versus NCM; #Po0.05 versus GCM/C by two-way
ANOVA; N= 4
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phosphorylation was higher in SKA-31-treated cells. As FAK
activation has been demonstrated to be upstream to the PI3K/
AKT pathway in macrophages,24,25 we investigated the cross-
talk among these kinases in microglia upon KCa3.1 channel
activation. In the presence of PF-228, the effect of SKA-31 on
FAK and AKT phosphorylation was inhibited while, in the
presence of LY294002, the SKA-31-dependent FAK phos-
phorylation was maintained, being AKT phosphorylation
inhibited (Figure 5c). These data indicate that KCa3.1
activation is upstream to FAK activation and that FAK
precedes AKT phosphorylation.
To define the role of the FAK/PI3K/AKT pathway in
phenotype polarization, microglia were treated with NCM
or GCM and LPS/IFNγ or IL-4 and incubated with PF-228
or LY294002. Both kinase inhibitors were ineffective on
NCM- and LPS/IFNγ-treated microglia but prevented GCM-
and IL-4-induced expression of anti-inflammatory genes
(Figure 6).
Discussion
GBM is the brain tumor with the lowest survival rate from
the time of diagnosis. Its aggressiveness is certainly aided
by the ability to produce cytokines and factors involved in
tuning down the local immune system response, resulting in
an inability to react against cancer cell proliferation and
invasion.26 One approach to fight GBM is to re-activate the
immune system starting with local microglia and infiltrating
macrophages, which constitute the first-line innate immune
defense in the brain.
In this study, we tested the hypothesis that targeting
microglial KCa3.1 channels could represent a therapeutic
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strategy to counteract GBM malignancy, helping microglia to
re-acquire a more pro-inflammatory, antitumor phenotype.
This hypothesis is supported by several recent findings
demonstrating the ability of the tumor microenvironment to
hamper microglia inflammatory reaction, inhibiting the main-
tenance of the M1-like (pro-inflammatory) phenotype initially
induced upon microglia interaction with glioma cells. We
demonstrated that the anti-inflammatory M/MΦ phenotype
induced by interaction with glioma could be significantly
attenuated, in favor of a pro-inflammatory state by modulating
the activity of KCa3.1.
Microglia cells isolated from glioma-bearing mice treated
with TRAM-34 had a phenotype clearly oriented toward the
pro-inflammatory, antitumor state, consistent with the reduc-
tion of tumor size observed in these animals. We cannot
exclude that, at least in vivo, the TRAM-34-induced phenotype
switch of M/MΦ could be secondary to a direct effect of the
drug on glioma.14 However, this would only partially explain
the effect, because similar effects on cell phenotype were
obtainedwith CD11b+ cells from humanGBMbiopsies treated
with TRAM-34 and with pure cultured microglia exposed to
GCM or IL-4. These data indicate that the block of KCa3.1 is
sufficient to hinder microglia phenotype switch, suggesting
that these channels could be directly involved in modulating
the microglia activation state. This is in line with previous
papers demonstrating that KCa3.1 inhibition affects microglia
proliferation, p38 MAPK phosphorylation, NF-κB activation
and nitric oxide generation.18,19 Similar results were obtained
when microglia were stimulated with cytokines: microglia
treated with IL-4 displayed increased levels of the anti-
inflammatory genes arg1, ym1, fizz1, cd163 and cd206, which
were all reduced upon TRAM-34 treatment. Consistently, in
IL-4-treated cells, we observed higher levels of kcnn4 and
recorded TRAM-34-sensitive currents.
Taken together, these data support the hypothesis that
KCa3.1 is involved in determining microglia phenotype, in
particular shifting glioma-induced cell polarization toward a
pro-inflammatory state. Interestingly, a shift of IL-4-polarized
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macrophage toward a pro-inflammatory phenotype was also
described for another cation channel, TRPM7,27 and a recent
reports describe that CSFR-1 inhibition has similar effects on
the polarization of tumor-associated macrophages (TAM),
downregulating M2-related genes, with consequent antitumor
effects.28 In accordance, inhibition of the mTOR kinase has
been reported to induce the polarization of glioma-induced
microglia toward the pro-inflammatory state.29 It is known that
glioma-exposed microglia have an increased tendency to
migrate, invade and phagocyte;14 here we also observed that
KCa3.1 inhibition affected these microglia functions, likely
contributing to the antitumor activity of TRAM-34, in addition to
the direct effect on glioma.14 We also reported that microglia
treated with the KCa3.1 channel activator SKA-31, or
polarized by IL-4, had similar increased migratory, invasive
and phagocytic activities, all significantly reduced by KCa3.1
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inhibition. Microglia migration varies according to their activa-
tion state.30,31 We report that IL-4-treated microglia upregu-
lated the chemokine receptors CXCR4 and CXCR6 and the
MMP-9, all effects being abolished by TRAM-34. Interestingly,
LPS/IFNγ treatment did not modify CXCR6 or MMP-9
expression, strongly inhibiting CXCR4 expression. This
reduction could contribute to the antitumor effect reported for
microglia in the pro-inflammatory state.12 IL-4 treatment
consistently increased microglia migration toward CXCL12
and CXCL16. Interestingly, similar reduction of MMP-12
is induced by TRAM-34 treatment of CD11b+ cells
isolated from GBM patients. These results confirm that the
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anti-inflammatory phenotype of microglia can be reverted by
TRAM-34, which, however, also affects some classic pro-
inflammatory features of microglia.16,18,19
Remarkably, we report that TRAM-34 did not affect
microglia functions (migration, invasion, phagocytosis) in the
absence of stimulation or upon LPS/IFNγ treatment, in
contrast to the inhibitory effects observed on activating
pathways induced by inflammatory stimuli, such as oligomeric
amyloid and LPS.19 This could be explained by the lower
expression level of kcnn4 and the lower functional expression
of KCa3.1 in comparison with anti-inflammatory phenotype, in
our experimental systems, that comprise in vivo, ex vivo and
in vitro conditions.
To describe the intracellular pathways involved in KCa3.1-
mediated control of microglia phenotype, we analyzed FAK
and PI3K/AKT signaling that have been demonstrated to be
activated in TAMs and involved in the M2-like microglia
polarization.23 We demonstrated that both kinases are
essential in movement, phagocytosis and invasion of GCM-
and IL-4-treated cells; that FAK and PI3K/AKT signaling in
microglia is downstream of KCa3.1 activation and that the
block of FAK phosphorylation hampers SKA-31-induced
PI3K/AKT activation. We hypothesize that KCa3.1 activation
could induce local Ca2+ influx leading to FAK and AKT
phosphorylation32,33 and that these signals are involved in
GCM- and IL-4-mediated microglia activation and polarization.
KCa3.1 inhibition with TRAM-34 inhibited all these events,
promoting the induction of antitumor signals.
Our data suggest that, in addition to being involved in
modulating microglia phenotype, KCa3.1 channels are differ-
entially expressed in the different activation states of microglia.
Microglia isolated from the brain of glioma-bearing mice and
from biopsies of patients with glioma had significant upregula-
tion of kcnn4, as well as microglia exposed to GCM or treated
with IL-4 (see also Ferreira et al.34). In all these samples,
KCa3.1 inhibition reduced kcnn4 expression, as already
described in human lung myofibroblasts and vascular smooth
muscle cells,35–37 suggesting a clear relation between
microglia activation state and the control of KCa3.1 transcrip-
tion. A relation between KCa3.1 expression level and
activation was already reported in T cells, where a Ca2+-
dependent mechanism involves JNK and AP1 (c-Fos/c-Jun
heterodimer) complex binding to the kcnn4 promoter.38
In summary, based on the data herein presented, we
propose KCa3.1 as a possible marker of M/MΦ in the pro-
tumor state, and thus a potential therapeutic target to induce
GBM-associated M/MΦ to re-acquire a pro-inflammatory,
antitumor activity. Of note, and important for future therapeutic
use, one TRAM-34 analog, Senicapoc (ICA-17043), has been
already used in phase-3 clinical trials, where it was considered
safe, with no clinically relevant changes in vital signs and
physical examination.39
Materials and Methods
Animals and cell lines. Experiments were approved by the Italian Ministry of
Health in accordance with the ethical guidelines on use of animals from the EC
Council Directive 2010/63/EU. We used C57BL/6 mice (Charles River, Calco, Italy).
Human GBM (GL-15 and U87MG) and murine glioma (GL261) cell lines were
cultured in FBS-supplemented DMEM.
Microglia polarization. Microglia were obtained from cerebral cortices of
postnatal day 0–2 mice40 and treated for 24–48 h with LPS 100 ng/ml+IFNγ
20 ng/ml (ImmunoTools, Friesoythe, Germany) or IL-4 20 ng/ml (ImmunoTools) for
cell polarization.
Patch clamp. Patch-clamp recordings were obtained using glass electrodes
(2–4 MΩ) filled with intracellular solution (see composition in Supplementary
Methods). Currents were recorded by whole-cell configuration at RT with
EPC-10HEKA amplifier (HEKA, Lambrecht/Pfalz, Germany). K+ currents were
elicited with voltage ramps (−120 mV to +40 mV, 200 ms) every 10 s. KCa3.1
conductances were calculated from the slope of the TRAM-34-sensitive KCa current
between − 80 and − 75 mV, where KCa3.1 currents are not 'contaminated' by
Kv1.3 (activable at voltages4− 40 mV) or inward rectifier K+ currents (appreciable
at voltages o− 80 mV). Cell capacitance was continuously monitored. KCa3.1
current density was determined as the TRAM-34-sensitive slope conductance/cell
capacitance. The prominent Kv current in pro-inflammatory microglia was blocked
with Kv1.3 blocker PAP-1 (1 μM).
Chemotaxis and invasion assays. Microglia stimulated with NCM or
GCM, and cytokine-polarized microglia were treated for 24 h with TRAM-34
(2.5 μM) or without. Cells were incubated 3 h at 37 °C with 10% FBS in the lower
chamber as chemoattractant or with chemokines (CXCL12, 50 nM; CXCL16, 1 nM,
Peprotech, London, UK). For invasion assay, microglia were plated on matrigel-
coated transwells (BD-Falcon, Milan, Italy) and the movement toward GCM
(from GL261, GL15 or U87MG) was investigated in the presence of TRAM-34
(2.5 μM) for 24 h.
Phagocytosis. Microglial cells were stimulated with GCM for 24 h with
TRAM-34 (2.5 μM). Alternatively, polarized microglia were treated with TRAM-34
(2.5 μM) for 24 h. Red fluorescent FluoSpheres (0.03%) (Invitrogen, Monza, Italy)
were added for 1 h, and the number of spheres per cell was counted.14
Real-time PCR. GCM-stimulated or cytokine-polarized microglia were treated
with TRAM-34 (2.5 μM). After 24 h, total RNA was extracted with Trizol reagent
(Invitrogen), quantified and retro-transcripted using IScript Reverse Transcription
Supermix (Bio-Rad, Milan, Italy). RT-PCR was carried out in a I-Cycler IQ Multicolor
RT-PCR Detection System (Bio-Rad) using SsoFast Eva Green Supermix
(Bio-Rad). The PCR protocol consisted of 40 cycles of denaturation at 95 °C for
30 s and annealing/extension at 58 °C for 30 s. The Ct values from each gene were
normalized to the Ct value of GAPDH. Relative quantification was performed using
the 2−ΔΔCt method and expressed as fold increase. Primer sequences are in
Supplementary Table S2.
Form factor calculation. Microglia were seeded on glass coverslips, treated
as necessary, fixed, permeabilized, blocked and stained with Alexa-Fluor 488
Phalloidin (Invitrogen) for 20 min together with Hoechst. Fluorescent images were
processed using the MetaMorph 7.6.5.0 software (Molecular Device, Sunnyvale,
CA, USA), and form factor was calculated according the formula: 4π area/
perimeter2.41
Western blotting analysis. For protein phosphorylation analysis, protein
samples were separated on 8.75% SDS-polyacrylamide gel electrophoresis and
analyzed by western immunoblot using the following primary antibodies: pFAK
(Tyr397, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1 : 200, pAKT (Ser473,
Cell Signaling, Danvers, MA, USA) 1 : 1000, FAK (Santa Cruz Biotechnology)
1 : 200, AKT (Cell Signaling) 1 : 1000, and Actin (Sigma Aldrich, Milan, Italy)
1 : 2000; HRP-tagged goat anti-rabbit IgG was used as a secondary antibody
(1 : 2000; Dako, Cernusco sul Naviglio, Milan, Italy); the detection was performed
through the chemiluminescence assay Immun-Star Western C Kit (Bio-Rad).
Densitometric analysis was carried out with the Quantity One software (Bio-Rad).
Tumor cell implantation and mice treatment. Eight-week-old male
C57BL/6 mice were anesthetized with chloralhydrate (400 mg/kg, i.p.) and
stereotaxically injected with 1 × 105 GL261 cells in 5 μl PBS, 2 mm right and
1 mm anterior to the bregma in the striatum at 3 mm depth with a Hamylton
syringe (Bonaduz, Switzerland). After 7 days, mice were daily treated with TRAM-34
(120 mg/Kg i.p.) or vehicle (peanut oil).
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Tumor volume analysis. After 17 days from GL261 injection, animals were
killed and the brains were isolated. Tumor volume was evaluated with hematoxylin–
eosin staining as previously described.42 Briefly, after staining, brain slices (20 μm
of thickness) were analyzed by the Image Tool 3.0 software (University of Texas,
Health Science Center, San Antonio, TX, USA). to measure the tumor area, and
volume was calculated according to the formula (volume= t ×ΣA), where A= tumor
area/slice and t= thickness.43,44
Isolation of CD11b+ cells. After 17 days from GL261 injection, mice were
deeply anesthetized and perfused with ice-cold PBS. Brains were removed
and digested with trypsin (0.25 mg/ml). Tissue suspension was applied to a 30-μm
cell strainer, labeled with CD11b MicroBeads and isolated accordingly to the
manufacturer's instructions (Miltenyi Biotec, Calderara di Reno, Bologna, Italy).
CD11b+ cell purity (99%) was verified as reported.42
Immunofluorescence. Coronal brain sections (20 μm) were washed in PBS,
blocked (3% goat serum in 0.3% Triton X-100) for 1 h at RTand incubated overnight
at 4 °C with specific antibodies, Iba1 (Dako) 1 : 500 and KCa3.1 (Alomone,
Jerusalem, Israel) 1 : 100. Brain slices were stained with the fluorophore-conjugated
secondary antibodies and Hoechst for nuclei visualization and analyzed using a
fluorescence microscope. Signals co-localization was analyzed measuring the
average fluorescence intensity (pixel) of merged signals.
Isolation of CD11b+cells from human GBM. Tumor specimens obtained
from adult patients who gave informed consent to the research proposals
(Neurosurgery Departments, Neuromed and Policlinico Umberto I) were processed
as described above to isolate CD11b+ cells. See Supplementary Table S1 for
patients' details. Cells were treated with TRAM-34 (2.5 μM) for 24 h and mRNAs
were analyzed by RT-PCR for human pro- and anti-inflammatory markers (primer
sequences are listed in Supplementary Table S2).
Statistical analysis. Data are expressed as the means± S.E.M. Student's
t-test, paired t-test, one-way or two-way analysis of variance (ANOVA) was
performed. A value of Po0.05 was considered significant. All statistical analyses
were carried out using the Sigma Plot 11.0 Software (Systat Software GmbH,
Erkrath, Germany).
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